Hudson To Succeed Brandicourt As Sanofi CEO
All change at the top for Sanofi which has poached Novartis pharma chief Paul Hudson to succeed Olivier Brandicourt as CEO.
You may also be interested in...
As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme.
The Basel-headquartered company has launched three high-profile drugs in the past couple of months. Analysts are waiting to see what initial impact these potential future growth drivers are having.
Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.